IMUC Stock Chart & Stats
$0.20
$0.03(13.96%)
At close: 4:00 PM EDT
$0.20
$0.03(13.96%)
Day’s Range― - ―
52-Week Range$0.04 - $0.34
Previous CloseN/A
Volume3.69K
Average Volume (3M)1.55K
Market Cap
$19.11M
Enterprise Value$32.30M
Total Cash (Recent Filing)$613.24K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta-0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding126,502,860
10 Day Avg. Volume364
30 Day Avg. Volume1,551
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)-3.75
Price to Sales (P/S)0.00
P/FCF Ratio-6.01
Enterprise Value/Market Cap1.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-102.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IMUC FAQ
What was ImmunoCellular Therapeutics’s price range in the past 12 months?
ImmunoCellular Therapeutics lowest stock price was $0.04 and its highest was $0.34 in the past 12 months.
What is ImmunoCellular Therapeutics’s market cap?
ImmunoCellular Therapeutics’s market cap is $19.11M.
When is ImmunoCellular Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmunoCellular Therapeutics’s earnings last quarter?
ImmunoCellular Therapeutics released its earnings results on Aug 13, 2018. The company reported -$0.1 earnings per share for the quarter.
Is ImmunoCellular Therapeutics overvalued?
According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued.
Does ImmunoCellular Therapeutics pay dividends?
ImmunoCellular Therapeutics does not currently pay dividends.
What is ImmunoCellular Therapeutics’s EPS estimate?
ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunoCellular Therapeutics have?
ImmunoCellular Therapeutics has 126,502,860 shares outstanding.
What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?
ImmunoCellular Therapeutics reported an EPS of -$0.1 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?
Currently, no hedge funds are holding shares in IMUC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmunoCellular Therapeutics
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion. EOM Pharmaceuticals Holdings, Inc. was founded in 2020 and is headquartered in Montvale, New Jersey.